The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many
relevant gene–drug associations have been discovered, but PGx-guided treatment needs to …

The application of pharmacogenetics holds great promise for individualized therapy.
However, it has little clinical reality at present, despite many claims. The main problem is that …

Background Pharmacogenetics offers the potential to improve health outcomes by
identifying individuals who are at greater risk of harm from certain medicines. Routine …

Most people in the developed world will sooner or later be given prescription drugs to treat
common diseases or to reduce the risk of getting them. Almost everyone who takes …

AIM Probably, the most important and potentially lethal adverse event of azathioprine (AZA)
and mercaptopurine (MP) is myelosuppression. Our aim was to conduct a review of AZA/MP …

Objective Due to extended application of pharmacogenetic and pharmacogenomic
screening (PGx) tests it is important to assess whether they provide good value for money …

For several decades, dermatologists have utilized azathioprine to treat numerous
debilitating skin diseases. This synthetic purine analog is derived from 6-mercaptopurine. It …

The activity of the enzyme thiopurine methyltransferase (TPMT) is regulated by a common
genetic polymorphism. One in 300 individuals lack enzyme activity and 11% are …